PE20141909A1 - Terapia combinada para el tratamiento del cancer de ovario - Google Patents

Terapia combinada para el tratamiento del cancer de ovario

Info

Publication number
PE20141909A1
PE20141909A1 PE2014001409A PE2014001409A PE20141909A1 PE 20141909 A1 PE20141909 A1 PE 20141909A1 PE 2014001409 A PE2014001409 A PE 2014001409A PE 2014001409 A PE2014001409 A PE 2014001409A PE 20141909 A1 PE20141909 A1 PE 20141909A1
Authority
PE
Peru
Prior art keywords
treatment
cancer
ovaric
patient
ovarian cancer
Prior art date
Application number
PE2014001409A
Other languages
English (en)
Inventor
Corrado Bernasconi
David Bollag
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141909(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20141909A1 publication Critical patent/PE20141909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q90/00—Systems or methods specially adapted for administrative, commercial, financial, managerial or supervisory purposes, not involving significant data processing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO DE UNA PACIENTE DIAGNOSTICADA CON CANCER OVARICO RESISTENTE AL PLATINO TAL COMO CANCER OVARICO EPITELIAL (EOC), UN CARCINOMA DE LAS TROMPAS DE FALOPIO (FTC) O UN CARCINOMA PERITONEAL PRIMARIO (PPC), QUE COMPRENDE LA ADMINISTRACION DE i) UN ANTICUERPO ANTI-VEGF TAL COMO BEVACIZUMAB EN UNA CANTIDAD DE 10 MG/KG POR VIA INTRAVENOSA CADA DOS SEMANAS, Y ii) UN QUIMIOTERAPEUTICO TAL COMO PACLITAXEL, TOPOTECAN O UNA DOXORRUBICINA LIPOSOMAL PEGILADA (PLD); EN DONDE DICHO TRATAMIENTO PROLONGA EL TIEMPO DE SUPERVIVENCIA LIBRE DE PROGRESION MEDIA DEL PACIENTE EN COMPARACION CON UN PACIENTE CON CANCER OVARICO RESISTENTE AL PLATINO QUE SOLO RECIBE DICHO QUIMIOTERAPEUTICO
PE2014001409A 2012-03-13 2013-03-11 Terapia combinada para el tratamiento del cancer de ovario PE20141909A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610128P 2012-03-13 2012-03-13
US201261653598P 2012-05-31 2012-05-31
US201261672987P 2012-07-18 2012-07-18

Publications (1)

Publication Number Publication Date
PE20141909A1 true PE20141909A1 (es) 2014-11-29

Family

ID=47844333

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001409A PE20141909A1 (es) 2012-03-13 2013-03-11 Terapia combinada para el tratamiento del cancer de ovario

Country Status (31)

Country Link
US (2) US20150098988A1 (es)
EP (2) EP3553083A1 (es)
JP (2) JP6563197B2 (es)
KR (1) KR102082363B1 (es)
CN (1) CN104334577A (es)
AR (1) AR090313A1 (es)
AU (2) AU2013231410B2 (es)
BR (1) BR112014018964A2 (es)
CA (2) CA2860941C (es)
CO (1) CO7000770A2 (es)
CR (1) CR20140400A (es)
CY (1) CY1121821T1 (es)
DK (1) DK2825558T3 (es)
EA (1) EA201400996A1 (es)
ES (1) ES2736030T3 (es)
HK (1) HK1202122A1 (es)
HR (1) HRP20191248T1 (es)
HU (1) HUE045445T2 (es)
IL (2) IL234174B (es)
LT (1) LT2825558T (es)
MX (1) MX365139B (es)
PE (1) PE20141909A1 (es)
PH (1) PH12014501543A1 (es)
PL (1) PL2825558T3 (es)
PT (1) PT2825558T (es)
RS (1) RS58964B1 (es)
SG (1) SG11201404417PA (es)
SI (1) SI2825558T1 (es)
TW (1) TW201343178A (es)
WO (1) WO2013135602A2 (es)
ZA (1) ZA201404843B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061002T2 (hu) 2011-09-23 2023-04-28 Mereo Biopharma 5 Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
ES2736030T3 (es) 2012-03-13 2019-12-23 Hoffmann La Roche Politerapia para el tratamiento del cáncer de ovario
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3353204B1 (en) * 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
WO2019005754A1 (en) * 2017-06-26 2019-01-03 The Cleveland Clinic Foundation TREATMENT AGAINST CANCER
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023207931A1 (zh) * 2022-04-26 2023-11-02 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
RO119721B1 (ro) 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
ES2256935T3 (es) 1997-04-07 2006-07-16 Genentech, Inc. Anticuerpos humanizadores y procedimiento para producirlos.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CN1829741A (zh) * 2003-05-30 2006-09-06 健泰科生物技术公司 利用抗－vegf抗体的治疗
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
SI2322556T1 (sl) 2004-09-03 2016-02-29 Genentech, Inc. Humanizirani antagonisti proti beta7 in njihove uporabe
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
MX2009006886A (es) * 2006-12-20 2009-09-02 J C Health Care Ltd Metodo para administracion de doxorubicina liposomal pegilada.
CN101646458A (zh) 2007-02-01 2010-02-10 健泰科生物技术公司 使用血管发生抑制剂的联合疗法
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US20110159080A1 (en) * 2008-06-03 2011-06-30 Colin Lowery Composition comprising liposome-entrapped doxorubicin and methods of administration
SI2361085T2 (sl) 2008-11-22 2018-11-30 F. Hoffmann-La Roche Ag Uporaba protitelesa proti vegf v kombinaciji s kemoterapijo za zdravljenje raka dojk
US20190185555A1 (en) 2017-12-19 2019-06-20 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CN103237810A (zh) 2010-02-23 2013-08-07 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
ES2736030T3 (es) 2012-03-13 2019-12-23 Hoffmann La Roche Politerapia para el tratamiento del cáncer de ovario

Also Published As

Publication number Publication date
JP6640288B2 (ja) 2020-02-05
BR112014018964A8 (pt) 2017-07-11
CA2860941A1 (en) 2013-09-19
HUE045445T2 (hu) 2019-12-30
MX365139B (es) 2019-05-24
US20150098988A1 (en) 2015-04-09
EP2825558A2 (en) 2015-01-21
US20160289317A1 (en) 2016-10-06
CO7000770A2 (es) 2014-07-21
TW201343178A (zh) 2013-11-01
PL2825558T3 (pl) 2019-11-29
AU2017258927A1 (en) 2017-11-30
CA3056813A1 (en) 2013-09-19
KR20140138691A (ko) 2014-12-04
AR090313A1 (es) 2014-11-05
KR102082363B9 (ko) 2023-05-02
LT2825558T (lt) 2019-08-12
CY1121821T1 (el) 2020-10-14
ES2736030T3 (es) 2019-12-23
CR20140400A (es) 2014-10-07
US11384142B2 (en) 2022-07-12
KR102082363B1 (ko) 2020-02-27
RS58964B1 (sr) 2019-08-30
IL263781A (en) 2019-01-31
HK1202122A1 (en) 2015-09-18
HRP20191248T1 (hr) 2019-10-18
MX2014010591A (es) 2014-09-18
EP2825558B1 (en) 2019-05-15
PH12014501543A1 (en) 2014-10-08
WO2013135602A3 (en) 2013-11-07
DK2825558T3 (da) 2019-07-22
JP6563197B2 (ja) 2019-08-21
JP2018193380A (ja) 2018-12-06
PT2825558T (pt) 2019-07-11
EA201400996A1 (ru) 2015-03-31
IL234174B (en) 2019-01-31
CN104334577A (zh) 2015-02-04
WO2013135602A2 (en) 2013-09-19
CA2860941C (en) 2019-11-05
ZA201404843B (en) 2015-08-26
BR112014018964A2 (pt) 2020-05-12
SG11201404417PA (en) 2014-10-30
JP2015511593A (ja) 2015-04-20
EP3553083A1 (en) 2019-10-16
AU2013231410A1 (en) 2014-07-17
SI2825558T1 (sl) 2019-08-30
AU2013231410B2 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
PE20141909A1 (es) Terapia combinada para el tratamiento del cancer de ovario
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
SMT201600132B (it) Derivati fosforammidati di 5-fluoro-2'-desossiuridina per uso nel trattamento del cancro
MX361218B (es) Análogos de spliceostatina.
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
PE20142363A1 (es) Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
NI201400032A (es) Piridopirazinas anticancerígenas via la
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EA201590783A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
UY36075A (es) Derivados de tubulisina
AR088391A1 (es) Fitocanabinoides para usar en el tratamiento de cancer de mama
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
SV2012004192A (es) Nuevo uso antitumoral de cabazitaxel
EA201400178A1 (ru) Лечение рака молочной железы
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
EA201690388A1 (ru) Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
EA201690528A1 (ru) Способы лечения злокачественной опухоли непрерывной инфузией кофермента q10
UY34178A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.
SG194735A1 (en) Compositions and methods for treating cancer
CY1117579T1 (el) Παραγωγα φαινυλιου-γουανiδiνης
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора
MX2014001810A (es) Uso de ccne2 como marcador de estratificacion en el tratamiento de tumores de mama con nuevos inhibidores de pan-cdk.
AR085105A1 (es) Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)

Legal Events

Date Code Title Description
FD Application declared void or lapsed